Nektar Therapeutics PE ratio NKTR

Share price divided by earnings per share over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 8.8×; Aug 2019
Peer median: 14.1×

Nektar Therapeutics has no meaningful PE ratio today: it lost $6.70 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in Aug 2019, at 8.8×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2019	8.8×	8.6×	11.7×
2018	8.5×	7.5×	13.6×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	396×	65.5×	464×

Against its peers

Companies in Drug Manufacturers - General nearest Nektar Therapeutics' size, closest first, today.

Company	PE ratio
NKTRNektar Therapeutics	n/m
OMEROmeros	10.9×
PCRXPacira BioSciences	104×
ANABAnaptysbio	10.7×
AMPHAmphastar Pharmaceuticals	14.8×
PAHCPhibro Animal Health	15.9×
ANIPANI Pharmaceuticals	15.4×
ABUSArbutus Biopharma	5.4×
HRMYHarmony Biosciences	11.7×
COLLCollegium Pharmaceutical	18.5×
PBHPrestige Consumer Healthcare	13.4×
Peer median	14.1×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Nektar Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.